Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/28799
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | VAN WIJMEERSCH, Bart | - |
dc.contributor.author | Barone, D. | - |
dc.contributor.author | Broadley, S. | - |
dc.contributor.author | Dive, D. | - |
dc.contributor.author | Hupperts, R. M. M. | - |
dc.contributor.author | Lycke, J. | - |
dc.contributor.author | Massacesi, L. | - |
dc.contributor.author | Montalban, X. | - |
dc.contributor.author | Naismith, R. T. | - |
dc.contributor.author | Pandey, K. | - |
dc.contributor.author | Schippling, S. | - |
dc.contributor.author | Vermersch, P. | - |
dc.contributor.author | Chung, L. | - |
dc.contributor.author | Daizadeh, N. | - |
dc.contributor.author | Rodriguez, C. E. | - |
dc.contributor.author | Nakamura, K. | - |
dc.contributor.author | Wiendl, H. | - |
dc.date.accessioned | 2019-07-24T12:56:03Z | - |
dc.date.available | 2019-07-24T12:56:03Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | MULTIPLE SCLEROSIS JOURNAL, 24, p. 488-489 | - |
dc.identifier.issn | 1352-4585 | - |
dc.identifier.uri | http://hdl.handle.net/1942/28799 | - |
dc.description.sponsorship | Sanofi; Bayer HealthCare Pharmaceuticals | - |
dc.language.iso | en | - |
dc.publisher | SAGE PUBLICATIONS LTD | - |
dc.subject.other | Clinical Neurology; Neurosciences | - |
dc.title | Alemtuzumab outcomes over 6 years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS I patients (TOPAZ study) | - |
dc.type | Journal Contribution | - |
local.bibliographicCitation.conferencedate | OCT 10-12, 2018 | - |
local.bibliographicCitation.conferencename | 34th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) | - |
local.bibliographicCitation.conferenceplace | Berlin, GERMANY | - |
dc.identifier.epage | 489 | - |
dc.identifier.spage | 488 | - |
dc.identifier.volume | 24 | - |
local.format.pages | 2 | - |
local.bibliographicCitation.jcat | M | - |
dc.description.notes | [Van Wijmeersch, B.] Hasselt Univ, BIOMED, Rehabil & MS Centre Overpelt, Hasselt, Belgium. [Barone, D.] Rowan Univ, Glassboro, NJ USA. [Broadley, S.] Griffith Univ, Sch Med, Gold Coast Campus, Southport, Qld, Australia. [Dive, D.] Univ Hosp Ctr Liege, Liege, Belgium. [Hupperts, R. M. M.] Maastricht Univ, Med Ctr, Orbis Med Ctr, Sittard, Netherlands. [Lycke, J.] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Gothenburg, Sweden. [Massacesi, L.] Univ Florence, Florence, Italy. [Montalban, X.] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada. [Montalban, X.] Hosp Univ Vall dHebron, Ctr Esclerosi Mfiltiple Catalunya Cemcat, Barcelona, Spain. [Naismith, R. T.] Washington Univ, Sch Med, St Louis, MO USA. [Pandey, K.] Hackensack Univ Hosp, Multiple Sclerosis Care Ctr, Hackensack, NJ USA. [Schippling, S.] Univ Hosp Zurich, Neuroimmunol & Multiple Sclerosis Res, Zurich, Switzerland. [Schippling, S.] Univ Zurich, Zurich, Switzerland. [Vermersch, P.] Univ Lille, Lille, France. [Chung, L.; Daizadeh, N.; Rodriguez, C. E.] Sanofi, Cambridge, MA USA. [Nakamura, K.] Cleveland Clin, Cleveland, OH 44106 USA. [Wiendl, H.] Univ Munster, Munster, Germany. | - |
local.publisher.place | LONDON | - |
local.type.refereed | Refereed | - |
local.type.specified | Meeting Abstract | - |
dc.identifier.isi | 000446861401257 | - |
item.fulltext | No Fulltext | - |
item.contributor | VAN WIJMEERSCH, Bart | - |
item.contributor | Barone, D. | - |
item.contributor | Broadley, S. | - |
item.contributor | Dive, D. | - |
item.contributor | Hupperts, R. M. M. | - |
item.contributor | Lycke, J. | - |
item.contributor | Massacesi, L. | - |
item.contributor | Montalban, X. | - |
item.contributor | Naismith, R. T. | - |
item.contributor | Pandey, K. | - |
item.contributor | Schippling, S. | - |
item.contributor | Vermersch, P. | - |
item.contributor | Chung, L. | - |
item.contributor | Daizadeh, N. | - |
item.contributor | Rodriguez, C. E. | - |
item.contributor | Nakamura, K. | - |
item.contributor | Wiendl, H. | - |
item.fullcitation | VAN WIJMEERSCH, Bart; Barone, D.; Broadley, S.; Dive, D.; Hupperts, R. M. M.; Lycke, J.; Massacesi, L.; Montalban, X.; Naismith, R. T.; Pandey, K.; Schippling, S.; Vermersch, P.; Chung, L.; Daizadeh, N.; Rodriguez, C. E.; Nakamura, K. & Wiendl, H. (2018) Alemtuzumab outcomes over 6 years in RRMS patients who switched from SC IFNB-1a: follow-up of CARE-MS I patients (TOPAZ study). In: MULTIPLE SCLEROSIS JOURNAL, 24, p. 488-489. | - |
item.accessRights | Closed Access | - |
crisitem.journal.issn | 1352-4585 | - |
crisitem.journal.eissn | 1477-0970 | - |
Appears in Collections: | Research publications |
Google ScholarTM
Check
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.